Overall verdict
Neutral
5.8/10
1-year performance
+24.30%
Score breakdown
Up 24.3% over 1 year, 100% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Valuation 1.2/10.
30 analysts, target +0.1% vs the price.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Bernard Zovighian
Founded
1958
Employees
16 000
Revenue / employee
379 225 USD
Next earnings
February 10, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.71%
- Bank of New York Mellon Corp1.96%
- FMR LLC1.06%
- Rest of the register94.26%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
105.95 USD
52-week low
74.66 USD
1-year performance
24.30%
Rising
Year-to-date performance
23.98%
Rising
Drawdown
0.00%
Near its high
Position in the 52-week range
100% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 1.9 times harder: once that risk is counted, its lead is thin.
$10,000 placed at the end of December 2000 are worth today
| Edwards Lifesciences | $622,040 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-54 % between December 2021 and July 2024. $10,000 placed at the top fell to $4,568. The world ETF, at worst: -53 %. The share has not returned to its high yet.
Edwards Lifesciences earned 10 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Edwards Lifesciences: $622,040
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 45.68 USD - 49.17 USD (2 methods agree)
The price implies growth of 14.96% per year; the company grows at 6.79%.
Gross margin 78.3%, net margin 14.9%, ROIC 8.9%, ROE 9.4%.
Net margin
14.90%
Exceptional
Sector 9.11%|S&P 13.40%
Gross margin
78.30%
High
Return on equity (ROE)
9.44%
High
Sector 7.42%|S&P 17.06%
Return on invested capital (ROIC)
8.87%
High
Free cash flow margin (FCF)
21.34%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.43x
High
Margin stability
17.0 pts
Very uneven
Revenue to net income
Growth
5.0/10Revenue up 10.5% over 1 year, 6.7% a year over 5, EPS 6.8% a year over 5.
Revenue (trailing 12 months)
6.7Md USD
Revenue growth (1y)
10.46%
Solid
Revenue growth (3y)
12.73%
Moderate
EPS growth (1y)
6.39%
Solid
EPS CAGR (5y)
6.79%
Low
EPS revisions (3 months)
0.52%
Revised up
Valuation
1.2/10P/E 61.7x, forward P/E 44.9x, EV/EBITDA 36.2x, PEG 9.09. The multiple sits in the 98th percentile of its own 5-year history.
P/E (TTM)
61.7x
Very expensive
Sector 29.2x|S&P 23.6x
Forward P/E
44.9x
Expensive
EV / EBITDA
36.2x
Very expensive
Sector 14.2x|S&P 15.5x
PEG
9.09
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
47.42 USD
Deeply overvalued
P/E vs its own 5-year history
among the 2% highest valuations
At its historical high
Market cap
60.9Md USD
Financial strength
10.0/10Cash covers 659.4% of the debt, net debt/EBITDA -2.0x.
Net debt / EBITDA
-2.0x
Net cash
Gearing (net debt / equity)
-35.95%
Net cash
Cash
4.6Md USD
Cash / market cap
7.63%
Tight
Cash / total debt
659.42%
Net cash
Interest coverage
69.3x
Very solid
Net debt
-3.9Md USD
Equity
11.0Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 104.01 USD
- MM2093.17
- MM5089.48
- MM20085.98
- RSI 1476.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.98%
200-day average slope, 3 months
+1.97%
50-day average slope, 1 month
+0.96%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.58 % per day
Volatility change
+2.30%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 2.36 (12) | 3.01 (29) | 6 810 (27) | 2 158 (16) | 1 370 (11) |
| 2027 | 3.24 (12) | 3.39 (29) | 7 480 (28) | 2 415 (17) | 1 852 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK | 6.5 | 6.1 | 121Md USD | 34.0x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -10.5 % | ||
| 2 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.2 % | ||
| 3 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 4 | MDT | 6.2 | 6.7 | 130Md USD | 25.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 9.3 % | ||
| 5 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 6 | EW | 5.8 | 5.1 | 60.9Md USD | 61.7x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 24.3 % | ||
| 7 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 8 | BDX | 5.5 | 5.3 | 58.4Md USD | 51.8x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 49.4 % | ||
| 9 | SHL | 5.3 | 5.3 | 53.1Md USD | 22.0x | 9.4 % | 7.3 % | 7.3 % | 2.8x | 4.3 % | 0.0 % |
